We are live on ! Find out more
PA

Profund Advisors Portfolio holdings

AUM $2.72B
1-Year Est. Return 47.27%
This Fund
S&P 500
This Quarter Est. Return
+9.01%
1 Year Est. Return
+47.27%
3 Year Est. Return
+155.16%
5 Year Est. Return
+217.35%
10 Year Est. Return
+932.28%
AUM
$2.7B
AUM Growth
+$129M
Cap. Flow
-$29.9M
Cap. Flow %
-1.11%
Top 10 Hldgs %
38.9%
Holding
1,194
New
46
Increased
298
Reduced
730
Closed
120

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$37.6M
2
AVGO icon
Broadcom
AVGO
+$3.78M
3
EXAS
Exact Sciences
EXAS
+$3.05M
4
BKNG icon
Booking.com
BKNG
+$2.84M
5
NEE icon
NextEra Energy
NEE
+$2.62M

Sector Composition

Rank Sector Weight
1 Technology 47.26%
2 Healthcare 11.3%
3 Consumer Discretionary 9.84%
4 Communication Services 9.16%
5 Financials 4.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SFNC icon
1001
Simmons First National
SFNC
$3.35B
$183K 0.01%
+10,413
New +$184K
VIPS icon
1002
Vipshop
VIPS
$6.84B
$183K 0.01%
14,037
-12,902
-48% -$205K
ALLO icon
1003
Allogene Therapeutics
ALLO
$601M
$177K 0.01%
76,160
-44,899
-37% -$132K
APLE icon
1004
Apple Hospitality REIT
APLE
$3.96B
$174K 0.01%
11,986
-323
-3% -$4.82K
AVXL icon
1005
Anavex Life Sciences
AVXL
$222M
$174K 0.01%
41,280
-61,758
-60% -$250K
LQDA icon
1006
Liquidia Corp
LQDA
$7.67B
$173K 0.01%
14,434
+3,466
+32% +$46K
WIT icon
1007
Wipro
WIT
$18.5B
$170K 0.01%
55,672
+2,282
+4% +$6.29K
ALTM
1008
DELISTED
Arcadium Lithium plc
ALTM
$169K 0.01%
50,286
-8,641
-15% -$36.1K
HRTX icon
1009
Heron Therapeutics
HRTX
$86.3M
$168K 0.01%
+48,073
New +$148K
PARA
1010
DELISTED
Paramount Global Class B
PARA
$167K 0.01%
16,083
+2,783
+21% +$32.6K
FLNA
1011
Filana Therapeutics
FLNA
$43M
$166K 0.01%
13,440
+591
+5% +$12.5K
SBRA icon
1012
Sabra Healthcare REIT
SBRA
$5.64B
$163K 0.01%
10,612
-1,139
-10% -$16.3K
MAC icon
1013
Macerich
MAC
$7.32B
$160K 0.01%
10,379
-1,285
-11% -$19.7K
BGC icon
1014
BGC Group
BGC
$5.58B
$160K 0.01%
19,245
-1,808
-9% -$14.9K
CCCC icon
1015
C4 Therapeutics
CCCC
$376M
$158K 0.01%
34,149
-92,101
-73% -$549K
IAG icon
1016
IAMGOLD
IAG
$8.47B
$155K 0.01%
41,283
+1,656
+4% +$6.31K
ORIC icon
1017
Oric Pharmaceuticals
ORIC
$1.25B
$155K 0.01%
21,861
+4,175
+24% +$37.4K
FATE icon
1018
Fate Therapeutics
FATE
$281M
$153K 0.01%
46,528
-65,823
-59% -$288K
DFTX
1019
Definium Therapeutics
DFTX
$5.73B
$150K 0.01%
+20,846
New +$182K
EBC icon
1020
Eastern Bankshares
EBC
$5.25B
$150K 0.01%
+10,694
New +$142K
GT icon
1021
Goodyear
GT
$2.07B
$148K 0.01%
13,058
-1,303
-9% -$15.9K
CABA icon
1022
Cabaletta Bio
CABA
$439M
$144K 0.01%
19,250
-35,177
-65% -$431K
AMRX icon
1023
Amneal Pharmaceuticals
AMRX
$5.72B
$143K 0.01%
22,522
+1,680
+8% +$10.7K
EQX icon
1024
Equinox Gold
EQX
$7.32B
$141K 0.01%
26,869
+1,788
+7% +$9.95K
SPRY icon
1025
ARS Pharmaceuticals
SPRY
$590M
$137K 0.01%
16,129
-1,303
-7% -$11.6K

Similar funds

Profund Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Profund Advisors held 1,194 positions worth $2.7B, up 5% from $2.57B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Profund Advisors's Q2 2024 filing shows 46 new, 298 increased, 730 reduced and 120 closed positions. Its largest new stake was HubSpot: 3,324 shares worth $1.96M. The largest sale was Apple, an estimated $22.4M.

By sector, the portfolio is most concentrated in Technology at 47% of assets, up from 43% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Profund Advisors's largest Q2 2024 buy was HubSpot: 3,324 shares worth $1.96M.
  • Profund Advisors added most to NVIDIA in Q2 2024, an estimated $37.6M increase.
  • Profund Advisors's biggest Q2 2024 reduction was Apple, cutting an estimated $22.4M.
  • Profund Advisors fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $3.01M.
  • Profund Advisors's ten largest holdings make up 39% of its $2.7B portfolio in Q2 2024.
  • Profund Advisors opened 46 new positions and closed 120 in Q2 2024.
  • Profund Advisors's portfolio value rose 5% quarter-over-quarter to $2.7B.

Based on Profund Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.